Has Jose Mendoza, MD received payments from drug or device companies?

Yes. Drug and device makers reported $321,280 in general payments to Jose Mendoza, MD across 655 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jose Mendoza, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jose Mendoza, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jose Mendoza, MD

Hematology & Oncology · Clinton, MDNPI 1982648036

Payments from drug & device makers

$321,280in general payments, 2019–2025

Across 655 payments — averaging $490.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

E.r. Squibb & Sons, L.L.C.$156K
Bristol Myers Squibb$112K
AstraZeneca$17K
Eli Lilly$13K
Beigene USA, Inc.$3K
Karyopharm Therapeutics Inc.$2K
plus $17K from 54 others

$38in research payments, 2019–2025

Across 1 payment — averaging $38.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$38

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
E.r. Squibb & Sons, L.L.C.	31	$156,371
Bristol Myers Squibb	16	$112,295
AstraZeneca(2 entities)	52	$16,707
Eli Lilly	2	$13,068
Beigene USA, Inc.	7	$2,608
Karyopharm Therapeutics Inc.	6	$2,405
Pfizer	41	$2,369
Pharmacosmos Therapeutics Inc.	6	$1,643
Daiichi Sankyo Inc.	21	$1,507
Rigel Pharmaceuticals, Inc.	5	$1,102
Johnson & Johnson(2 entities)	47	$1,090
Novartis	40	$969
Merck	40	$884
AbbVie	20	$502
Bayer	15	$443
Genentech USA, Inc.	19	$430
Takeda Pharmaceuticals U.S.A., Inc.	14	$405
Sanofi	13	$387
Pharmacyclics LLC, An Abbvie Company	16	$339
Eisai Inc.	15	$316
Amgen	15	$311
Gilead(2 entities)	14	$305
Astellas Pharma US Inc	13	$291
Lilly USA, LLC	9	$254
Incyte Corporation	10	$217
Sobi, Inc	9	$215
GSK	9	$215
Novocure GmbH	1	$200
Seagen Inc.	9	$196
Puma Biotechnology, Inc.	10	$179
Regeneron Healthcare Solutions, Inc.	6	$177
Tersera Therapeutics LLC	6	$163
Array Biopharma Inc	7	$152
Pharmaessentia USA Corporation	5	$149
Spectrum Pharmaceuticals Inc.	5	$113
AVEO Pharmaceuticals, Inc.	4	$111
Kyowa Kirin, Inc.	5	$101
Comsort, Inc	1	$100
Heron Therapeutics, Inc.	3	$96
Taiho Oncology, Inc.	4	$94
Mirati Therapeutics, Inc.	4	$91
EMD Serono, Inc.	4	$89
Acrotech Biopharma Inc.	5	$87
EUSA Pharma (US) LLC	4	$85
Jazz Pharmaceuticals Inc.	4	$85
Stemline Therapeutics Inc.	3	$83
Agios Pharmaceuticals, Inc.	3	$73
Exelixis Inc.	3	$72
Ipsen Biopharmaceuticals, Inc	3	$69
Immunocore Limited	2	$60
Celltrion USA Inc.	2	$60
Myovant Sciences Inc.	2	$50
Tempus AI, Inc	2	$49
CTI Biopharma Corp.	3	$47
G1 Therapeutics, Inc.	2	$42
Morphosys, US Inc.	2	$41
Deciphera Pharmaceuticals Inc.	2	$36
Alnylam Pharmaceuticals Inc.	2	$35
Blue Earth Diagnostics	1	$35
Servier Pharmaceuticals LLC	2	$35

How this compares

$321,280 in reported general payments places this provider in the 80th percentile of 242 hematology & oncology providers in Maryland.

See all hematology & oncology providers in Maryland →

Medicare billing

Part B allowed, 2024

$4,114,617

Medicare patients

1,132

Services billed

186,900

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Clinton

Jun SunClinton$216K
Robert KreitmanOlney$54.2M
Ralph BocciaBethesda$12.1M
Dan ZandbergBaltimore$9.9M
Ani BalmanoukianBaltimore$6.6M
Mark MarkowskiBaltimore$5.9M
Giuseppe GiacconeBethesda$5.4M
Ivana GojoBaltimore$5M
Suman RaoBaltimore$4.2M
Tim GretenBethesda$4.2M

See the full list for Maryland →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →